netFormulary NHS
North East and North Cumbria
ICS Formulary
 Search
 Results

Looking for Nivolumab found 30 matches

Formulary items 3 matches
   
Open monograph to display formulary status BNF Category
  Cytotoxic Drug Nivolumab  (Opdivo®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Nivolumab-relatlimab  (Opdualag®) Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
  Cytotoxic Drug Ipilimumab  (Yervoy®) Malignant disease and immunosuppression - Ipilimumab - 08.01.05
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
link in drug section MHRA Drug Safety Update (July 2017): Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection (08.01.05)
link in drug section MHRA Drug Safety Update (Oct 2019): Nivolumab (Opdivo): reports of cytomegalovirus (CMV) gastrointestinal infection or reactivation (08.01.05)
link in drug section NICE TA1065:Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma (08.01.05)
link in drug section NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
link in drug section NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma (08.01.05)
link in drug section NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (08.01.05)
link in drug section NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (08.01.05)
link in drug section NICE TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA684: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (08.01.05)
link in drug section NICE TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (08.01.05)
link in drug section NICE TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (08.01.05)
link in drug section NICE TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (08.01.05)
link in drug section NICE TA724: Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small- cell lung cancer (08.01.05)
link in drug section NICE TA736: Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (08.01.05)
link in drug section NICE TA746: Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (08.01.05)
link in drug section NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA817: Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (08.01.05)
link in drug section NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (08.01.05)
link in drug section NICE TA865: Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (08.01.05)
link in drug section NICE TA876: Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (08.01.05)
link in drug section NICE TA950: Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (08.01.05)
link in drug section NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (08.01.05)
link in drug section NICE TA964: Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (08.01.05)


 
netFormulary